Total Payments
$751,068
2024 Payments
$97,809
Companies
28
Transactions
348
Medicare Patients
673
Medicare Billing
$169,790
Payment Breakdown by Category
Consulting$392,652 (52.3%)
Other$148,877 (19.8%)
Research$142,152 (18.9%)
Travel$61,253 (8.2%)
Food & Beverage$6,133 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $392,652 | 124 | 52.3% |
| Unspecified | $142,152 | 12 | 18.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $134,550 | 41 | 17.9% |
| Travel and Lodging | $61,253 | 69 | 8.2% |
| Honoraria | $13,327 | 7 | 1.8% |
| Food and Beverage | $6,133 | 94 | 0.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,000 | 1 | 0.1% |
Payments by Type
General
$608,916
336 transactions
Research
$142,152
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $218,273 | 85 | $0 (2024) |
| Glenmark Pharmaceuticals Inc. | $124,213 | 4 | $0 (2018) |
| PFIZER INC. | $50,853 | 33 | $0 (2024) |
| Celgene Corporation | $47,433 | 23 | $0 (2022) |
| Janssen Research & Development, LLC | $43,262 | 8 | $0 (2024) |
| GENZYME CORPORATION | $40,254 | 29 | $0 (2024) |
| Adaptive Biotechnologies Corporation | $31,127 | 19 | $0 (2024) |
| GlaxoSmithKline, LLC. | $30,984 | 14 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $22,559 | 18 | $0 (2024) |
| Janssen Biotech, Inc. | $21,070 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $97,809 | 50 | PFIZER INC. ($22,585) |
| 2023 | $103,465 | 56 | Janssen Research & Development, LLC ($33,737) |
| 2022 | $60,001 | 33 | GlaxoSmithKline, LLC. ($20,820) |
| 2021 | $80,304 | 30 | Amgen Inc. ($35,896) |
| 2020 | $54,284 | 28 | Amgen Inc. ($9,725) |
| 2019 | $79,634 | 49 | Amgen Inc. ($41,774) |
| 2018 | $197,100 | 61 | Glenmark Pharmaceuticals Inc. ($124,213) |
| 2017 | $78,470 | 41 | Amgen Inc. ($46,957) |
All Payment Transactions
348 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $29.46 | General |
| Category: NONE | ||||||
| 12/17/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $37.01 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Amgen Inc. | Kyprolis (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $67.02 | General |
| 12/10/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $142.14 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Oncology | ||||||
| 12/06/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,100.00 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $4,155.00 | General |
| 11/14/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $51.81 | General |
| Category: Oncology | ||||||
| 10/15/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,875.00 | General |
| 10/07/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,988.00 | General |
| Category: Oncology | ||||||
| 09/24/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $45.69 | General |
| 09/24/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $18.28 | General |
| 09/24/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $14.43 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,986.00 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,155.00 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $50.00 | General |
| 08/19/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $5,982.00 | General |
| Category: Oncology | ||||||
| 08/12/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,094.00 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | Cash or cash equivalent | $276.44 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $346.61 | General |
| 08/06/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $142.01 | General |
| 08/06/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $95.47 | General |
| 08/06/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $91.93 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Clinical Perspectives on depth of response and correlation with long term outcome | Amgen Inc. | $7,334 | 1 |
| Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Amgen Inc. | $4,506 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | Takeda Pharmaceuticals U.S.A., Inc. | $2,100 | 1 |
| Ph3 KRd vs VRd study in Newly Diagnosed; transplant eligible population | Amgen Inc. | $2,000 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| Pooled analysis of KRd ISS studies in NDMM | Amgen Inc. | $678.70 | 1 |
| Minimal Residual Disease Status as a Surrogate Endpoint for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis | Amgen Inc. | $48.89 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 161 | 452 | $199,914 | $53,478 |
| 2022 | 2 | 203 | 371 | $168,861 | $44,478 |
| 2021 | 2 | 107 | 252 | $115,731 | $31,992 |
| 2020 | 3 | 202 | 457 | $242,575 | $39,842 |
Total Patients
673
Total Services
1,532
Medicare Billing
$169,790
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 135 | 426 | $182,754 | $49,380 | 27.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $17,160 | $4,099 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 95 | 238 | $102,102 | $29,736 | 29.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 66 | 91 | $39,039 | $8,423 | 21.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $19,800 | $4,842 | 24.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $7,920 | $1,478 | 18.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 74 | 219 | $93,951 | $27,036 | 28.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 33 | 33 | $21,780 | $4,956 | 22.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 111 | 273 | $188,370 | $24,980 | 13.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 70 | 163 | $33,415 | $11,745 | 35.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 21 | 21 | $20,790 | $3,117 | 15.0% |
About Dr. Carl Landgren, MD
Dr. Carl Landgren, MD is a Hematology & Oncology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/28/2014. The National Provider Identifier (NPI) number assigned to this provider is 1972926871.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carl Landgren, MD has received a total of $751,068 in payments from pharmaceutical and medical device companies, with $97,809 received in 2024. These payments were reported across 348 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($392,652).
As a Medicare-enrolled provider, Landgren has provided services to 673 Medicare beneficiaries, totaling 1,532 services with total Medicare billing of $169,790. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Miami, FL
- Active Since 01/28/2014
- Last Updated 11/02/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1972926871
Products in Payments
- Kyprolis (Drug) $100,008
- Kyprolis (Biological) $81,055
- DARZALEX (Drug) $50,135
- SARCLISA (Biological) $31,676
- clonoSEQ (Device) $31,127
- DARZALEX (Biological) $30,261
- Blincyto (Biological) $24,103
- KEYTRUDA (Biological) $13,867
- FREELITE (Device) $13,709
- Revlimid (Drug) $12,959
- EMPLICITI (Biological) $12,311
- XPOVIO (Drug) $11,744
- ELREXFIO (Drug) $10,210
- VENCLEXTA (Drug) $6,600
- CD38 (Drug) $5,879
- NINLARO (Drug) $2,535
- DUPIXENT (Biological) $2,247
- TECVAYLI (Biological) $2,170
- Pomalyst (Drug) $1,125
- Nplate (Biological) $1,100
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Miami
Dr. Steven Fein, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Dr. Fernando De Zarraga, M.d, M.D
Hematology & Oncology — Payments: $649,574
Hematology & Oncology $649,574
Mr. Neil Nagovski, Md, MD
Hematology & Oncology — Payments: $533,284
Hematology & Oncology $533,284
Srikanth Nagalla, Md, MD
Hematology & Oncology — Payments: $510,589
Hematology & Oncology $510,589
Raja Mudad, Md, MD
Hematology & Oncology — Payments: $442,163
Hematology & Oncology $442,163
Mikkael Sekeres, Md, MD
Hematology & Oncology — Payments: $383,274
Hematology & Oncology $383,274